DMD is a severe, progressive neuromuscular disorder caused by mutations in the dystrophin gene, resulting in muscle degeneration and loss of function. Current standard-of-care glucocorticoid therapy may slow disease progression but is associated with significant long-term adverse effects. Tegacorat is a selective glucocorticoid receptor agonist and modulator (SEGRAM) that has demonstrated anti-inflammatory activity with reduced glucocorticoid receptor-mediated transactivation in clinical and nonclinical studies.
Age
4–6
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male participant aged ≥4 years and \<7 years at randomization.
Clinically and genetically confirmed diagnosis of Duchenne muscular dystrophy.
Body weight between 13 kg and 35 kg at screening.
Able to walk independently without assistive devices.
Able to complete the TTSTAND assessment without assistance in less than 10 seconds.
Evidence of varicella immunity by serology or vaccination history.
Parent(s)/legal guardian(s) provide informed consent and participant assent as required.